Premium
Retinoic acid decreases fetal lung mesenchymal cell proliferation in vivo and in vitro
Author(s) -
Dalvin Sussie,
Komatsuzaki Katsumi,
Anselmo Mark A.,
Kling David E.,
Schnitzer Jay J.,
Kinane T. Bernard
Publication year - 2004
Publication title -
development, growth and differentiation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 66
eISSN - 1440-169X
pISSN - 0012-1592
DOI - 10.1111/j.1440-169x.2004.00745.x
Subject(s) - mesenchymal stem cell , mesenchyme , retinoic acid , microbiology and biotechnology , cell growth , mapk/erk pathway , biology , tretinoin , cell culture , signal transduction , chemistry , biochemistry , genetics
Retinoic acid (RA) is an important coordinator of mammalian organogenesis. RA is implicated in critical lung developmental events. Cell proliferation is precisely regulated during development. We investigated the effect of RA on proliferating mesenchymal cells in both whole organ lung cultures and cell cultures. The potential pathways required for the response were studied in cultures of lung mesenchymal cells from embryonic day (e) 12. We observed an RA‐dependent reduction in proliferation of mesenchymal cells in both whole organ and in cell culture. In mesenchymal cell cultures, RA decreased proliferation in lung mesenchymal cells by 72%. This was associated with a decrease of erk‐1/2 activity by 68%. Mesenchymal cell proliferation is erk‐1/2 dependent. Erk‐1/2 can be activated by G‐protein coupled receptors (GPCR) or tyrosine kinase receptors (RTK). RA treatment altered both the RTK and the GPCR pathways in primary lung mesenchymal cells. The Epidermal Growth Factor (EGF) dependent erk‐1/2 activation was increased by 35% whereas the G i ‐protein cascade was inhibited by 44% in cells treated with RA. Our results suggest that RA decreases proliferation of lung mesenchyme via a G i ‐protein and the erk‐1/2 signaling cascade.